ARWR Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Developments:
Arrowhead Pharmaceuticals (ARWR) has recently announced positive topline results from its ARO-C3 trial, demonstrating significant reductions in complement activity and proteinuria in patients with IgA nephropathy. This has bolstered confidence in the company's complement disease franchise and its future market potential. H.C. Wainwright has reiterated a Buy rating and an $80 price target for ARWR, citing the promising results and strategic pipeline advancements.
Technical Analysis:
The stock is currently trading at $16.3, with key technical indicators suggesting a potential bullish reversal. The RSI (14) is at 34.22, indicating the stock is oversold and due for a rebound. The MACD is showing signs of convergence, and the Fibonacci support level at $14.89 could act as a strong floor for the stock.
Price Prediction and Recommendation:
Based on the positive news sentiment and oversold technical indicators, we predict the stock will see a short-term rebound. The target price for the next trading week is $17.50, with a potential upside driven by the positive trial results and analyst sentiment.
Recommendation: Buy ARWR with a target price of $17.50.
ARWR Similar Chart Price Prediction
The price of ARWR is predicted to go up 11.64%, based on the high correlation periods with ICFI. The similarity of these two price pattern on the periods is 96.52%.
ARWR
ICFI
Up: 11.64%Similarity: 96.52%
ARWR Revenue Forecast
ARWR EPS Forecast
ARWR FAQs
What is ARWR revenue forecast for next quarter？
What is ARWR eps forecast for next quarter？
ARWR Analyst's Forecast
William Pickering
Bernstein
Hold
2024-11-29
Price Target
$27 → $24
Downside
-7.8%
Bernstein lowered the firm's price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company's fiscal Q4 update centered primarily on the large collaboration deal announced with Sarepta (SPRT) and implications for its own strategy going forward, the analyst tells investors in a research note. The firm takes a "very positive view" on the deal, both for its transformational impact on Arrowhead's cash position and the greater focus it will bring to the wholly-owned pipeline. The one downside about the deal is that" it dries up the catalyst path somewhat and may lead to ARWR being put in the funding short bucket," contends Bernstein.
Edward Tenthoff
Piper Sandler
Buy
2024-11-27
Price Target
$62 → $45
Upside
+72.48%
Shawn Egan
Citigroup
Hold
2024-11-27
Price Target
$27 → $26
Downside
-0.34%
